Cycle Pharmaceuticals and LeMed Specialty Pharmacy Collaboration
Today, Cycle Pharmaceuticals has officially partnered with LeMed Specialty Pharmacy, appointing them as the exclusive distributor for HARLIKU™ (nitisinone) Tablets. This marks a significant step in delivering the first FDA-approved treatment aimed at reducing urinary homogentisic acid (HGA) for adults suffering from Alkaptonuria (AKU).
Significance of HARLIKU™ for AKU Patients
HARLIKU™ represents a breakthrough for patients diagnosed with AKU, a rare metabolic disorder leading to debilitating health consequences. Cycle Pharmaceuticals aims to provide essential support alongside the medication, ensuring that patients receive comprehensive care tailored to their circumstances.
LeMed Specialty Pharmacy's Unique Approach
LeMed Specialty Pharmacy stands out in the industry with over two decades of expertise in supporting patients with rare diseases. Their dedication to personalized care and patient satisfaction aligns perfectly with Cycle's mission, setting the foundation for a lasting partnership.
Commitment to Patient Care
Chikai Lai, SVP & CCO at Cycle Pharmaceuticals, expressed excitement over this collaboration, emphasizing the goal of prioritizing patient accessibility to the necessary treatments. With LeMed's focus on rare disease management, every patient with AKU will have increased access to HARLIKU™, enhancing their overall treatment experience.
Benefits of HARLIKU™ Treatment
The introduction of HARLIKU™ is transforming the treatment landscape for AKU patients. As the only FDA-approved drug of its kind, it inhibits an enzyme responsible for HGA production, effectively reducing levels by up to 97%. Clinical studies have noted substantial improvements in patient well-being, including enhanced energy levels, decreased pain, and overall better physical function.
Tailored Support for Patients
Alongside HARLIKU™, Cycle Pharmaceuticals offers Cycle Vita™, a program designed to provide individualized guidance and support throughout the treatment process. This comprehensive approach ensures that patients are not only receiving a medication but are also equipped with resources that enable positive health outcomes.
Highlights of LeMed's Operations
LeMed's operations are significantly characterized by their commitment to independence, functioning without private investments or affiliations with pharmacy benefit managers. This allows them to focus solely on their patients and their unique needs, ensuring a beneficial experience that resonates with values of reliability and excellence.
Looking Forward
As patients and healthcare providers anticipate the launch of HARLIKU™, the collaboration between Cycle Pharmaceuticals and LeMed Specialty Pharmacy sets a promising example of how dedicated partnerships can drive innovation in patient care. With clear strategies and goals, the two companies aim to redefine how treatments are delivered to those affected by rare diseases.
Frequently Asked Questions
What is HARLIKU™?
HARLIKU™ (nitisinone) is the first FDA-approved treatment for reducing urinary homogentisic acid (HGA) in adults with Alkaptonuria (AKU).
Why is Cycle Pharmaceuticals partnering with LeMed Specialty Pharmacy?
This partnership aims to enhance access to HARLIKU™ for AKU patients across the U.S., ensuring they receive optimal support and care during their treatment journey.
What distinguishes LeMed Specialty Pharmacy?
LeMed Specialty Pharmacy is known for its focus on rare diseases, providing personalized care without the influence of external investments, thus maintaining a patient-first mentality.
How does HARLIKU™ work?
HARLIKU™ works by inhibiting an enzyme that contributes to the production of HGA, leading to significant reductions in HGA levels and improvements in the overall health of patients with AKU.
Is there additional support for patients using HARLIKU™?
Yes, Cycle Pharmaceuticals offers Cycle Vita™, a program designed to provide individualized support ranging from onboarding to continuous product assistance throughout the treatment process.
